论文部分内容阅读
据2002年美国神经外科学会年会报道,Toussaint等通过对有和无规律阿司匹林服用史的患者进行比较,研究了急性蛛网膜下腔出血(SAH)患者的转归,证实脑动脉瘤患者进行阿司匹林治疗是非常安全的。 以往的研究认为,正在接受抗凝治疗的患者发生SAH时的死亡率增加,而阿司匹林服用史对SAH的影响还不清楚。作为一种血小板抑制剂,阿司匹林是否会使出血更严重或更容易发生再出血是人们非常关心的问题。
According to the annual meeting of the American Academy of Neurosurgery in 2002, Toussaint et al. Studied the outcomes of patients with acute subarachnoid hemorrhage (SAH) by comparing patients taking aspirin with or without regular aspirin, and confirmed that patients with cerebral aneurysms had aspirin Treatment is very safe. Previous studies suggest that the mortality rate of SAH in patients undergoing anticoagulant therapy is increased, while the effect of aspirin administration on SAH remains unclear. As a platelet inhibitor, whether aspirin causes bleeding more serious or more likely to occur rebleeding is a matter of great concern.